| Nov 20 |
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
|
| Nov 6 |
C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
|
| Nov 6 |
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
|
| Nov 5 |
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
|
| Nov 1 |
C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Oct 31 |
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates
|
| Oct 31 |
C4 Therapeutics GAAP EPS of -$0.35 beats by $0.05, revenue of $15.36M beats by $10.76M
|
| Oct 31 |
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Oct 29 |
We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely
|
| Oct 28 |
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
